dyspepsia
DYSPEPSIA

Dyspepsia is having any one of the following: Disturbing postprandial fullness, early satiation, epigastric pain and/or burning felt predominantly in the upper abdomen.

It is considered a symptom complex rather than a specific diagnosis.

Acid suppression is the recommended initial therapy.

History

  • A detailed medical, social (eg smoking and alcohol intake) and family history reduces the differential diagnoses
  • Review medications for possible causes of dyspepsia eg Ca antagonists, nitrates, theophyllines, bisphosphonates, steroids and nonsteroidal anti-inflammatory drugs (NSAIDs), Aspirin, Acarbose, Orlistat, potassium supplements

Physical Examination

  • Often normal except for epigastric tenderness
  • Other PE findings may help diagnose or exclude other diseases eg right upper quadrant pain with cholelithiasis, palpable abdominal mass in hepatoma, lymphadenopathy in gastric malignancy

Laboratory Tests

  • Complete blood counts and chemistries (eg LFTs, pancreatic amylase) may be performed to identify alarm features or metabolic diseases causing dyspepsia or to investigate patients who have been unresponsive to treatment

Complications

Evaluation of Alarm Symptoms 

  • Symptoms that suggest complicated disease must be recognized and patients referred immediately for further diagnostic testing
    • GI bleeding
    • Epigastric mass
    • Iron-deficiency anemia
    • Persistent vomiting
    • Progressive dysphagia
    • Suspicious barium meal
    • Unintentional weight loss
    • Persistent nocturnal symptoms
    • Family history of upper GI cancer
    • Lymphadenopathy
    • Jaundice
    • Painful swallowing

Non-ulcer Dyspepsia or Functional Dyspepsia

  • Patients have >1 bothersome dyspepsia symptoms (eg epigastric pain or burning, early satiety, postprandial fullness) and without evidence of structural disease, including a normal upper endoscopy, that can explain the symptoms
  • Includes subcategories that can overlap: 
    • Postprandial distress syndrome (dyspepsia symptoms caused by meals): Includes 1 or both of the following for at least 3 days/week: Bothersome postprandial fullness or early satiety 
    • Epigastric pain syndrome (dyspepsia symptoms that do not occur exclusively postprandially and can be improved by meals): Includes at least 1 of the following for at least 1 day/week: Bothersome epigastric pain and/or burning   
  • Criteria must be fulfilled for postprandial distress syndrome and/or epigastric pain syndrome and fulfilled for the last 3 months with symptoms starting at least 6 months prior to diagnosis (Rome IV criteria)
  • No evidence is documented on routine evaluation (including upper endoscopy) of organic, systemic or metabolic disease that can explain the symptoms
  • Patients with this diagnosis should be treated similarly as those with uninvestigated dyspepsia provided they meet the following criteria:
    • No heartburn
    • No NSAID or low-dose Aspirin use
    • Normal blood tests
    • No evidence of an abnormality
  • H pylori eradication therapy is effective for patients with H pylori-positive functional dyspepsia 
    • Patients without symptoms 6-12 months following H pylori eradication therapy can be classified as H pylori-associated functional dyspepsia 
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).